Cellink AB (publ)

Cellink AB is a company that is involved in the healthcare industry. It is a company that provides an advanced bioprinting solutions for the healthcare sector. It offers 3D bioprinting of human organs and tissues.

Cellink AB was founded in Gothenburg, Sweden on January 27, 2016. The company originated from a collaboration between a consulting company, Chalmers University of Technology and other industrial partners. The purpose of the collaboration was to find a suitable biomaterial for 3D bioprinting of human cartilage.

Erik Gatenholm, co-founder and CEO of Cellink, started his first biomedical device company known as BC Genesis at age 18 in Blacksburg, Virginia in 2008 to commercialize a licensed university technology. BC Genesis focused on developing cellulose based medical implants for applications such as meniscus/cartilage repair as well as surgical meshes. In 2014, Erik moved to Sweden to complete his MBA at Gothenburg University, focusing on the commercialization of biotechnology startups. After meeting Hector Martinez at Chalmers University in late 2014, they begun to work to commercialize the biomaterial innovation behind Cellink. Gatenholm and Martinez realized the potential for the new biomaterial as a printable material and founded the company Cellink to provide bioinks to the 3D printing field. On November 3, 2016, Cellink was listed on Nasdaq First North 10 months after founding. The IPO was oversubscribed by 1070%, and raised 23 million SEK for the company.

Cellink offers bioinks, 3D bioprinters, and other consumables for research applications in the field of 3D bioprinting. The company seeks to provide both mobile 3D printers along with bioinks for the printing of mammalian tissues. Currently, Cellink offers two bioprinters, the Inkredible and Inkredible+, the major difference between the two being the Clean Chamber Technology and the Heated Cartridge holders in the Inkredible+. Additionally, Cellink offers several bioinks including Cellink, Cellink A, and Cellink Start.